{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Corrales E"],"funding":["Deutsches Krebsforschungszentrum (DKFZ)","Bundesministerium für Bildung und Forschung","Deutsche Forschungsgemeinschaft","Deutschen Konsortium für Translationale Krebsforschung"],"pagination":["187"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9700886"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity of the tumors hampers the success of therapies targeting the MAPK/ERK pathway alone. Dissecting this heterogeneity will contribute to identifying key players in the oncogenic progression to tailor more effective therapies.<h4>Methods</h4>We performed a comprehensive molecular and phenotypic characterization of a panel of patient-derived BRAF<sup>V600E</sup>-positive melanoma cell lines. Transcriptional profiling was used to identify groups of coregulated genes whose expression relates to an increased migratory potential and a higher resistance.<h4>Results</h4>A decrease in sensitivity to MAPK/ERK pathway inhibition with vemurafenib o"],"journal":["Cell communication and signaling : CCS"],"pubmed_title":["PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma."],"pmcid":["PMC9700886"],"funding_grant_id":["GRK2344","FKZ 01ZZ1801B"],"pubmed_authors":["Mertes R","Kowar S","Corrales E","Lemke S","Boerries M","Munch J","Levit-Zerdoun E","Lehmann A","Metzger P"],"additional_accession":[]},"is_claimable":false,"name":"PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.","description":"<h4>Background</h4>Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity of the tumors hampers the success of therapies targeting the MAPK/ERK pathway alone. Dissecting this heterogeneity will contribute to identifying key players in the oncogenic progression to tailor more effective therapies.<h4>Methods</h4>We performed a comprehensive molecular and phenotypic characterization of a panel of patient-derived BRAF<sup>V600E</sup>-positive melanoma cell lines. Transcriptional profiling was used to identify groups of coregulated genes whose expression relates to an increased migratory potential and a higher resistance.<h4>Results</h4>A decrease in sensitivity to MAPK/ERK pathway inhibition with vemurafenib o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T20:36:30.31Z","creation":"2025-02-19T04:36:57.966Z"},"accession":"S-EPMC9700886","cross_references":{"pubmed":["36434616"],"doi":["10.1186/s12964-022-00989-y"]}}